The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single-arm, open-label phase 2 study. METHODS: Eligible patients with platinum-treated, advanced/metastatic disease received oral mocetinostat (at a dose of 70 mg 3 times per week [TIW] escalating to 90 mg TIW) in 28-day cycles in a 3-stage study (ClinicalTrials.gov identifier NCT02236195). The primary endpoint was the objective response rate. RESULTS: Genomic testing was feasible in 155 of 175 patients (89%). Qualifying tumor mutations were CREBBP (15%), EP300 (8%), and both CREBBP and EP300 (1%). A total of 17 patients were enrolled into stage 1 (the intent-to-treat population); no patients were enrolled in subsequent stages. One partial response was observed (11% [1 of 9 patients; the population that was evaluable for efficacy comprised 9 of the 15 planned patients]); activity was deemed insufficient to progress to stage 2 (null hypothesis: objective response rate of ≤15%). All patients experienced ≥1 adverse event, most commonly nausea (13 of 17 patients; 77%) and fatigue (12 of 17 patients; 71%). The median duration of treatment was 46 days; treatment interruptions (14 of 17 patients; 82%) and dose reductions (5 of 17 patients; 29%) were common. Mocetinostat exposure was lower than anticipated (dose-normalized maximum serum concentration [C max ] after TIW dosing of 0.2 ng/mL/mg). CONCLUSIONS: To the authors' knowledge, the current study represents the first clinical trial using genomic-based selection to identify patients with urothelial cancer who are likely to benefit from selective histone deacetylase inhibition. Mocetinostat was associated with significant toxicities that impacted drug exposure and may have contributed to modest clinical activity in these pretreated patients. The efficacy observed was considered insufficient to warrant further investigation of mocetinostat as a single agent in this setting. Cancer 2019;125:533-540.
INTRODUCTION
Worldwide, urothelial carcinoma of the upper urinary tract and bladder results in 165,000 deaths annually. 1 The majority of patients with metastatic disease experience disease progression despite platinum-based chemotherapy, and salvage chemotherapy is reported to have only modest efficacy. 2, 3 Recently, 5 immune checkpoint inhibitors were approved for patients with platinum-refractory urothelial carcinoma and, although the anti-programmed cell death protein 1 (PD-1) agent pembrolizumab has improved overall survival (OS) versus chemotherapy in this setting, many patients do not benefit from such therapy. 4 Consequently, new treatment options are needed.
Dysregulated histone acetylation is implicated in the pathogenesis of several cancers, including urothelial carcinoma. Acetylation of chromatin by histone acetyltransferases (HATs) generally is associated with elevated transcription, whereas deacetylation, mediated by histone deacetylases (HDACs), is associated with repressed transcription. 5, 6 Histone acetylation can become dysregulated through the upregulation of HDACs and/or genetic inactivation of HATs, resulting in the silencing of tumor supressor and other genes. 5, 6 Inhibition of HDAC1 and HDAC2 resulted in antitumor activity in urothelial carcinoma in vitro, whereas elevated HDAC1 is linked with poor prognosis in patients with urothelial carcinoma. 7, 8 HDAC inhibitors have demonstrated promise in clinical trials across a range of tumor types, and several have been approved by the US Food and Drug Administration, including vorinostat for patients with cutaneous T-cell lymphoma, romidepsin for patients with cutaneous T-cell lymphoma and peripheral T-cell lymphoma, belinostat for patients with peripheral T-cell lymphoma, and panobinostat for patients with multiple myeloma. 9 Mocetinostat is an investigational HDAC inhibitor that targets class I and class IV HDACs (isoforms 1, 2, 3, and 11), 10 and has demonstrated antitumor activity in patients with hematologic malignancies. [11] [12] [13] In vivo, mocetinostat induces cell cycle arrest and apoptosis and inhibits tumor growth. 10 Furthermore, a HAT inactivation signature associated with muscle-invasive bladder cancer was found to be inversely influenced by mocetinostat in breast cancer cells.
14 Mocetinostat also demonstrated preferential activity in CREB binding protein (CREBBP)-mutated and/or E1A binding protein p300 (EP300)-mutated (HAT genes) xenograft models and solid tumor cell lines, including urothelial cell carcinoma (see Supporting Tables S1 and  S2 and Supporting Fig. S1 ). Thus, we hypothesized that treating patients with urothelial carcinoma harboring inactivating mutations in CREBBP and EP300 with selective HDAC inhibitors may restore the expression of tumor suppressor genes, resulting in antitumor responses.
This phase 2 study investigated single-agent mocetinostat in patients with locally advanced or metastatic urothelial carcinoma who previously were treated with platinum-based chemotherapy and inactivating tumor mutations or deletions in CREBBP and/or EP300.
MATERIALS AND METHODS

Patients and Study Design
The current phase 2, open-label, single-arm, 3-stage, multicenter study was conducted between November 2014 and July 2016 (ClinicalTrials.gov identifier NCT02236195). Patients with histologically confirmed, locally advanced, unresectable or metastatic urothelial (transitional cell) carcinoma who developed disease progression after receipt of platinum-based chemotherapy were recruited. Eligible patients had adequate bone marrow, hepatic, and renal function and an inactivating mutation or deletion (homozygous or hemizygous) in CREBBP and/or EP300 (see Supporting Materials). Genomic prescreening of tumor tissue (primary or metastatic; archival tissue was permitted if a fresh biopsy was not available) was performed centrally using next-generation sequencing (Foundation Medicine, Cambridge, Massachusetts) or a sponsorapproved, local sequencing platform (FoundationOne [Foundation Medicine] and MSK-IMPACT [Memorial Sloan Kettering Cancer Center, New York, New York]) or next-generation sequencing (Oncopanel; Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts) capturing the full coding regions for CREBBP and EP300. Key exclusion criteria included prior or current treatment with an HDAC inhibitor and symptomatic or uncontrolled brain metastases.
Oral mocetinostat (Mirati Therapeutics Inc, San Diego, California) was administered in continuous 28-day cycles at a starting dose of 70 mg 3 times per week (TIW) for stage 1 of the study. Escalation to 90 mg TIW on day 1 of cycle 2 was planned for patients without treatment-related grade ≥3 adverse events (AEs), and 90 mg TIW was the planned starting dose for the cohorts in stage 2 and stage 3 of the study. Mocetinostat was continued until disease progression or unacceptable AEs occurred.
The protocol was approved by the institutional review boards at each institution, and the study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.
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Study Endpoints and Assessments
The primary endpoint was the objective response rate (ORR; complete response and partial response [PR] as per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1 ). Secondary endpoints included duration of response, progression-free survival (PFS; overall and at month 4), OS, 1-year survival rate, safety, and pharmacokinetics.
Computed tomography scans for tumor evaluation were performed at baseline and at 8-week intervals for the first 12 months and at 12-week intervals thereafter. AEs were graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).
Plasma concentrations of mocetinostat were determined using high-performance liquid chromatography and tandem mass spectrometry during stage 1 (before the dose and 1 hour after the dose on day 1 of cycles 1 and 2) with more timepoints planned for stage 2.
Tumor total mutation burden was estimated retrospectively in the 322 target genes included in FoundationOne for patients with central testing (see Supporting Materials).
Statistical Analyses
The primary endpoint, ORR, was assessed using an exact test for a single proportion (2-sided α=0.05; ORR ≤15% [H 0 ] vs >15% [H 1 ]) in a 3-stage study design to include 15 patients, 18 patients, and 67 patients, respectively, in the population that was evaluable for efficacy (patients meeting the entry criteria who received mocetinostat and had at least baseline and one on-study disease assessment) (see Supporting Materials). Safety was assessed in patients receiving ≥1 dose of mocetinostat. Pharmacokinetics were evaluated in all patients with sufficient data. Timeto-event efficacy endpoints were estimated using KaplanMeier methodology (see Supporting Materials).
RESULTS
Patient Disposition and Baseline Disease Characteristics
Of the 175 patients who consented to undergo genomic screening, testing was feasible for 155 (89%; sample quantity/quality was insufficient for 20 patients). Alterations included truncating mutations, gene amplifications, homozygous deletions, annotated recurrent missense mutations, and missense variants of uncertain significance (variants of unknown significance were excluded from the main study analysis) that were present in ≥10% of the population. The 150 patients included 144 patients who were tested centrally at Foundation Medicine and 6 patients who were tested at local institutions. An arrow (↓) denotes a patient enrolled in the clinical trial (reports from 5 patients tested locally were not available, including 4 patients who were prescreened using FoundationOne testing and including 2 enrolled patients).
a In cases of CCND1 amplification, this co-occurred with fibroblast growth factor 3 (FGF3), FGF4, or FGF19 amplification in >80% of cases. In addition, a significant correlation for the co-occurrence of retinoblastoma protein (RB1) and TP53 mutations and CREB binding protein (CREBBP) and STAG2 mutations and the mutual exclusivity of cyclin-dependent kinase inhibitor 2A (CDKN2A) homozygous deletion and TP53 mutation or mouse double minute 2 homolog (MDM2) amplification and TP53 mutation was observed. ARID1A indicates AT-rich interaction domain 1A; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; EP300, E1A binding protein p300; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha. cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) ( Fig. 1) . Thirty-three patients (21%) had ≥1 of the 40 qualifying tumor mutations in CREBBP or EP300 identified: 27 CREBBP mutations were identified among 23 patients (15%), 13 EP300 mutations were identified among 12 patients (8%), and mutations in both genes were identified in 2 patients (1%). Each qualifying mutation was observed only once within the study. Qualifying CREBBP alterations were most commonly nonsense (5% [8 patients]), frameshift (5% [7 patients]), or missense (3% [5 patients]) mutations. EP300 mutations were most commonly missense mutations (3% [5 patients]). Nonqualifying mutations in CREBBP and EP300 (putative passenger mutations) were detected in 18 patients (12%) (see Supporting Table S3) .
Seventeen of 33 patients with qualifying mutations were enrolled into stage 1 (Fig. 2) ; baseline demographic and disease characteristics of the enrolled patients are shown in Table 1 . Twenty-two qualifying mutations were identified in these 17 patients: 14 CREBBP mutations in 12 patients and 8 EP300 mutations in 7 patients, and 2 patients had qualifying mutations of both CREBBP and EP300 (see Supporting Table S3 ). Sixteen patients with qualifying mutations were not enrolled, most often because they were receiving an earlier line of therapy (Fig. 2) . The patients received a median of 2 prior systemic therapies (range, 1-5 prior systemic therapies) ( Table 1 ) and all had discontinued mocetinostat at the time of analysis, most due to disease progression (53%) The population evaluable for efficacy included all patients in the ITT population who met prespecified entry criteria and had at least a baseline and 1 on-study disease assessment that were adequate for evaluation using Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Cancer February 15, 2019 or AEs (24%) (Fig. 2) . Based on the decision of the sponsor, the current study was closed after the enrollment of 17 patients, including 9 patients in the population that was evaluable for efficacy (8 patients withdrew from mocetinostat treatment prior to the on-study disease assessment [4 due to AEs and 3 due to symptomatic deterioration, and 1 patient withdrew consent]); patients were not recruited for stages 2 and 3 of the current study.
Efficacy
One objective response was observed in the population of patients who were evaluable for efficacy. This PR lasted 3.9 months and occurred in a 67-year-old man with disease restricted to the lymph nodes. His primary tumor contained 2 qualifying EP300 missense mutations (G1347E and P925T) and other mutations (truncating mutations in ARID1A, MLL2 [KMT2D], and CHEK2; a missense mutation in ATM; and amplification of TERC and PRKCI). The ORR of 11% (95% confidence interval [95% CI], 0.3%-48%) was not statistically significant (null hypothesis of ≤15% could not be rejected; P=1.00). Two patients (22%) were found to have achieved stable disease lasting 3.5 months and 3.8 months, respectively, and progressive disease was reported in 6 patients (67%) (see Supporting Fig. S2 ). The median PFS was 57 days (95% CI, 23-117 days) in the population of patients who were evaluable for efficacy. The estimated PFS at 4 months was 10% (95% CI, 0%-40%); the PFS at 1 year could not be estimated. The median OS was 3.5 months (95% CI, 2.1-15.7 months) and the 1-year survival rate was 30% (95% CI, 10%-60%) in the intent-to-treat (ITT) population (all patients who received the study medication). Similar efficacy results were observed in the population that was evaluable for efficacy and the ITT population.
Safety
The median duration of mocetinostat therapy was 46 days (range, 8-225 days), and the cumulative median dose administered was 930 mg (range, 280-7730 mg). The median relative dose intensity was 99% (range, 37%-117%) during cycle 1 and was 84% (range, 14%-117%) in subsequent cycles. Eleven of the 17 enrolled patients initiated ≥2 treatment cycles. The dose of mocetinostat was escalated from 70 mg TIW to 90 mg TIW in 9 patients (4 of whom received ≤1 full cycle of mocetinostat at a dose of 90 mg TIW). Five patients (29%) underwent dose reductions due to AEs (3 patients; 18%) or other reasons (2 patients; 12%), and 14 patients (82%) had at least 1 dose interruption, most commonly due to AEs (11 patients; 65%).
All patients experienced ≥1 treatment-emergent (all causality) AE, and the majority of patients (14 patients; 82%) experienced ≥1 treatment-related AE. The most frequent treatment-emergent AEs were nausea (13 patients; 77%), fatigue (12 patients; 71%), decreased appetite (8 patients; 47%), and diarrhea (8 patients; 47%) ( Table 2) ; these events also were the most frequent treatmentrelated AEs. Grade ≥3 treatment-related AEs were fatigue and hyponatremia (in 2 patients each, respectively; 12%). A total of 21 treatment-emergent serious AEs were reported in 10 patients (59%), including vomiting, lower gastrointestinal hemorrhage, abdominal pain, and pericardial effusion (2 patients each; 12%). One serious AE of pericardial effusion was assessed as being related to mocetinostat (both pericardial effusion events resolved). Ten patients died during the study, all due to their underlying disease.
Pharmacokinetics
Due to the limited blood sampling schedule for stage 1 of the current study, the 1-hour post-dose sample was considered representative of the maximum serum concentration (C max ) based on data from prior studies Cancer February 15, 2019 (see Supporting Information), and pharmacokinetic analyses were restricted to C max and time to C max . After a single 70-mg dose of mocetinostat, the mean C max was found to be 105 ng/mL. The mean dosenormalized C max was 1.2 ng/mL/mg and intersubject variability (coefficient of variation, geometric mean) was 90%. After multiple TIW doses of mocetinostat of 50 mg and 90 mg, respectively, the mean C max was 41 ng/mL and 39 ng/mL (see Supporting Table S4 ). The mean dose-normalized C max was 0.2 ng/mL/mg and the intersubject variability was 423%.
DISCUSSION
Inactivating alterations of CREBBP and EP300 are relatively frequent (approximately 13% and approximately 15%, respectively) in patients with urothelial carcinoma 14, 16, 17 and are implicated in the dysregulation of key acetylation pathways and oncogenesis. 18, 19 Based on promising findings in urothelial carcinoma cell lines and tumor models (see Supporting Tables S1 and S2 and Supporting Fig. S1 ), we postulated that patients with urothelial carcinoma and inactivating alterations in CREBBP and/or EP300 could be treated by class I HDAC inhibition via a mechanism of increased histone acetylation leading to an open chromatin state with decreased transcriptional repression of tumor suppressor genes. Although the maximum tolerated dose of mocetinostat as a single agent was determined to be 110 mg TIW in other tumor settings, a lower recommended dose of 90 TIW was considered for the current study based on prior observations of pericardial infusion and balancing pharmacodynamic and clinical data as well as regulatory guidance. 20 However, single-agent mocetinostat at doses up to 90 mg TIW demonstrated only modest activity in this cohort of heavily pretreated patients with factors indicative of a poor prognosis. The ORR of 11% and the finding that of 9 evaluable patients, only 1 patient (with lymph nodeonly disease and multiple genomic alterations) was alive and free of disease progression for 4 months was not consistent with meaningful clinical activity. Although mocetinostat-related AEs, including gastrointestinal events and fatigue, were consistent with the safety profiles reported in other settings, 11, 12, 21 frequent dose interruptions and reductions were required. Mocetinostat exposure (mean dose-normalized C max of 0.2 ng/mL/mg) was lower than in prior trials of mocetinostat TIW (range, 0.8-1.6 ng/mL/mg). It is feasible that underlying disease and prior treatments may have contributed to limited functional reserve, resulting in poor tolerability. These findings underscore the limitations of preclinical models in predicting clinical activity and toxicity issues related to anticancer treatments. Further evaluation of mocetinostat at lower doses may be useful for guiding dose reduction in future study protocols to maximize each patient's exposure to treatment.
Studies of other HDAC inhibitors in patients with urothelial carcinoma reported mixed results, with responses noted with single-agent vorinostat but not when vorinostat was combined with doxorubicin or docetaxel. [22] [23] [24] An ORR of 20% was reported in a small study of belinostat or panobinostat, and prolonged stable disease was noted in 1 of 3 patients with urothelial carcinoma who were treated with entinostat plus 13-cis-retinoic acid. 25, 26 These data suggest that HDAC inhibitors can be active in patients with urothelial carcinoma, but predictive biomarkers are needed for patient selection. To our knowledge, data regarding genomic predictors of response to HDAC inhibitors are limited. In a phase 2 study of panobinostat in patients with recurrent diffuse large B-cell lymphoma, mutations in MEF2B were found to be associated with response, whereas 14 genes, including TOX4, PSMD 13 , and CCNK, were associated with resistance to vorinostat based on a study of human colon cancer cell lines. 27, 28 To our knowledge, this is the first clinical trial using genomic-based selection to identify patients with urothelial carcinoma for treatment with selective HDAC inhibition. The results of the current study demonstrate the feasibility of this approach while also providing genomic tumor characterization for this population of patients.
There was considerable genomic variation in CREBBP and EP300, with each qualifying mutation observed only once in the current study. It is interesting to note that the patient with a confirmed PR harbored 2 EP300 mutations in trans, P925T, and G1347E, suggesting that biallelic loss of function in this pathway could be therapeutically significant; however, this patient had lymph node-only metastasis, which is a favorable prognostic factor. It is feasible that mocetinostat activity might be greater as an earlier line of therapy when a longer duration of treatment may be feasible and potentially confer meaningful disease-modifying activity. Furthermore, we hypothesized a mechanism of action of mocetinostat to reactivate the transcription of tumor suppressor genes, but a relatively high frequency of inactivating alterations in the tumor suppressor genes TP53, CDKN2A/B, and RB1 may have limited the potential of epigenetic modulation by mocetinostat to induce tumor response. Potential future treatment strategies could include combining mocetinostat with an inhibitor of PD-1/ programmed death-ligand 1 (PD-L1) to take advantage Cancer February 15, 2019 of the former's potential immunomodulatory effects. Indeed, mocetinostat has been shown to increase the expression of PD-L1 and augment PD-1/PD-L1 checkpoint blockade immunotherapy. 29 Other combination partners could be considered within the appropriate molecular context.
In summary, single-agent mocetinostat was found to be associated with significant toxicities and limited activity in heavily pretreated patients with advanced/metastatic urothelial carcinoma and poor prognostic factors. Few patients received the intended dose of 90 mg TIW, which may have compromised efficacy. Nevertheless, the clinical activity observed does not warrant the further investigation of mocetinostat as a single agent in this setting. Mocetinostat currently is being investigated in other tumors and in combination with immunotherapy.
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